Skip to main content

Multiplex Assays: Increasing Prevalence of Cancer, Infectious Diseases and Pharmaceutical Industry Driving Market Growth



What are the key factors driving growth in Multiplex Assays Market?

In the current market scenario, there is a growing demand for multiplex assays. The major factors driving the growth of the market include the adoption of Companion Diagnostics for increasing the safety & efficacy of therapies and the advantages of multiplex assays over conventional singleplex assays.

How global multiplex assays market will grow in coming years?

The global
multiplex assays market is projected to reach USD 3.35 Billion in 2023 from USD 2.17 Billion in 2017, at CAGR of 7.5%.

Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=61593314

Consumables Segment to Dominate The Market:

On the basis of product & service, the market is broadly segmented into instruments, consumables, and software & services. The consumables segment is expected to account for the largest share of the market; it is also the fastest-growing segment of the multiplex assays market. This can be attributed to the recurring purchase of assays and reagents for increasing research applications.

Which Geography to Create More Business Growth Opportunities?

The APAC market is projected to register the highest growth rate during the forecast period primarily due to its pharmaceutical market, which is growing at the fastest pace in the world, the availability of a large number of qualified researchers, and increasing prevalence of cancer and infectious diseases.

Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=61593314

Key Market Players:

The key players in the global multiplex assays market are Luminex (US), Bio-Rad Laboratories (US), Becton Dickinson (US), Illumina (US), and Thermo Fisher Scientific (US).

Most companies focus on agreements, collaborations, and partnerships to compete in the market. The players also focus on increasing their presence in high-growth markets through acquisitions and product launches. Illumina (US), Luminex (US), and Bio-Rad Laboratories (US) focus on product launches, partnerships, and agreements to strengthen their position in the market.

In 2017, Illumina was the leading player in the multiplex assays market. The company has a strong geographic presence across the US, Europe, Greater China, and Asia Pacific. The company focuses on offering consumables and analyzers in the multiplex assays market. Illumina concentrates on inorganic strategies to maintain its leader position in this market. For instance, in 2017, the company partnered with Integrated DNA Technologies (US) to provide improved library preparation multiplexing and target enrichment solutions for the next-generation sequencing (NGS) market. The agreement will see IDT and Illumina leveraging their expertise in the genomics field to deliver enhanced tools for sequencing. Similarly, in 2015, the company acquired GenoLogics Life Science Software Inc. (Canada) to integrate their life science software as part of the overall Illumina informatics solution.


Comments

Popular posts from this blog

NGS-Based RNA-Sequencing Industry is Growing at a CAGR of 20%

NGS-based RNA-sequencing Market growth is driven mainly by the advantages of RNA-seq over conventional technologies; an increasing number of RNA-seq grants; rising number of research activities involving RNA-seq; and rapid growth in precision medicine market. NGS-based RNA-sequencing Market: Impact Analysis 1. NGS-Based RNA-Sequencing: Market Overview 2. Geographical Snapshot of the NGS-Based RNA-Sequencing Market 3. Rapid Growth in Precision Medicine 4. Growing Number of Research Activities Involving RNA-Seq 5. Increasing Applications of RNA-Seq in Research ( Cancer and Agricultural) The NGS-based RNA-sequencing market size is estimated to grow from USD 1.7 billion in 2019 to USD 4.2 billion by 2024, at a CAGR of 20.0%. Key Questions Addressed in The Report: 1. Who are the top 10 players operating in the global NGS-based RNA-sequencing market? 2. What are the drivers, restraints, opportunities, and challenges in the NGS-based RNA-sequencing Industry? 3. What are th...

Digital Diabetes Management Market to Reach $19.98 billion by 2024 | Market and Regional Growth Analysis

  Digital diabetes management solutions are smartphone-connected diabetes management devices and software platforms used by patients suffering from Type 1, Type 2, and gestational diabetes. Medical professionals also use these solutions to manage diabetes. Various digital diabetes management devices such as smart glucose meters, continuous glucose monitoring systems, smart insulin pens, and smart insulin pumps/closed-loop systems and smart insulin patches are used for glucose monitoring and insulin delivery. Diabetes management applications, data management software & platforms, and services are used by patients and healthcare providers for remote monitoring, data analysis, and disease management. The Digital Diabetes Management Market is experiencing significant growth due to rising prevalence of diabetes has increased the focus on the development and adoption of better solutions for diabetes care. Also, advancements in technologies have ensured the introduction of highly...

Epigenetics Market | Major Market Dynamics Impacting The Global Industry

Epigenetics refers to the covalent modification of DNA, RNA, or protein that results in changes to the function and/or regulation of these molecules, without altering their primary sequences. These modifications can occur naturally, or can be influenced, by several factors including age, environment, disease state, and changes in lifestyle. Expanding application areas of epigenetics in non-oncology diseases, personalized medicine, and target therapy are expected to provide growth opportunities for players operating in the epigenetics market in the coming years. The growth in this market is primarily attributed to decreasing sequencing costs, increasing research activity, funding for epigenetics research, rising prevalence of cancer and growing applications of epigenetics in non-oncology diseases. Epigenetic changes such as dysregulation of DNA methylation are associated with cancer development and progression. Epigenetics provides new opportunities for deriving therapeutic strateg...